All In Biotech

Drug Trial Radar · NCT07951411

Evaluating the Efficacy and Safety of SAL0167 Tablets at Different Doses in Participants With Hyperlipidemia.

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of SAL0167 Tablets at Different Doses in Participants With Hyperlipidemia.

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Dec 31, 2026

Primary completion

Jul 30, 2027

Study completion Jul 30, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter phase II clinical trial. The purpose of this study is to evaluate the efficacy and safety of SAL0167, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hyperlipidemia. Participants will be randomized 1:1:1:1 to receive low-dose SAL0167, medium-dose SAL0167, high-dose SAL0167, or placebo for a treatment period of 8 weeks.

Conditions

  • Hyperlipidemia

Interventions

  • SAL0167 Dose 1Drug

    SAL0167 Dose 1

  • SAL0167 Dose 2Drug

    SAL0167 Dose 2

  • SAL0167 Dose 3Drug

    SAL0167 Dose 3

  • placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)Time frame: to Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.